Published in Eur J Cancer on January 01, 1994
Reversal of tumor-induced immunosuppression by TGF-beta inhibitors. Invest New Drugs (2003) 1.09
Tumor associated regulatory dendritic cells. Semin Cancer Biol (2012) 1.08
Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention. Clin Dev Immunol (2012) 0.89
Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality. Clin Lung Cancer (2010) 0.88
Mechanisms of immune response regulation in lung cancer. Transl Lung Cancer Res (2014) 0.86
Immunotherapy in lung cancer. Br J Cancer (1998) 0.86
Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer. Physiol Genomics (2014) 0.82
Lung cancer vaccines. Cancer J (2011) 0.82
Transforming growth factor beta can be a parameter of aggressiveness of pT1 colorectal cancer. World J Gastroenterol (2005) 0.81
Selective suppression of cytokine secretion in whole blood cell cultures of patients with colorectal cancer. Br J Cancer (1998) 0.75
Transforming Growth Factor-beta: A Therapeutic Target for Cancer. Hum Vaccin Immunother (2017) 0.75
FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex. Cell (1996) 12.07
Two CD95 (APO-1/Fas) signaling pathways. EMBO J (1998) 10.42
Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) Nature (1995) 8.23
Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science (1989) 7.76
Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J (1995) 7.60
Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature (1997) 6.23
Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion? Nat Med (1996) 5.09
Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature (1995) 4.95
The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ (2003) 4.72
Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J (1995) 4.68
Increased expression of Ia antigens on resting B cells: an additional role for B-cell growth factor. Proc Natl Acad Sci U S A (1984) 4.62
FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J (1997) 4.56
T cell-derived B cell differentiation factor(s). Effect on the isotype switch of murine B cells. J Exp Med (1982) 4.51
Serological, biochemical, and functional identity of B cell-stimulatory factor 1 and B cell differentiation factor for IgG1. J Exp Med (1985) 4.47
T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. J Exp Med (1992) 4.31
FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem (1996) 3.72
Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis. Nature (1995) 3.59
The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem (1999) 3.32
Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med (1995) 3.20
Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest (1993) 3.13
FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity (2000) 2.99
Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem (2001) 2.94
p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med (1998) 2.91
Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol (1990) 2.72
Mathematical modeling reveals threshold mechanism in CD95-induced apoptosis. J Cell Biol (2004) 2.70
Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med (1996) 2.65
Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J Biol Chem (1999) 2.52
Activation interferes with the APO-1 pathway in mature human T cells. Int Immunol (1993) 2.45
B-cell growth factor (B-cell growth factor I or B-cell-stimulating factor, provisional 1) is a differentiation factor for resting B cells and may not induce cell growth. Proc Natl Acad Sci U S A (1985) 2.41
FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol (2001) 2.39
Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest (1997) 2.32
Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res (1997) 2.32
FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b. J Biol Chem (1997) 2.29
TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ (2005) 2.25
Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med (1999) 2.24
Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke. Cell Death Differ (2001) 2.08
Divergent signalling via APO-1/Fas and the TNF receptor, two homologous molecules involved in physiological cell death. EMBO J (1994) 2.05
Specific binding of alloantigens to T cells activated in the mixed lymphocyte reaction. J Exp Med (1976) 2.04
Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum (1995) 2.03
HIV-1 Tat potentiates TNF-induced NF-kappa B activation and cytotoxicity by altering the cellular redox state. EMBO J (1995) 2.01
Differences between CD95 type I and II cells detected with the CD95 ligand. Cell Death Differ (1999) 1.99
Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis. Curr Opin Immunol (1998) 1.96
Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J Immunol (1992) 1.94
The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res (2000) 1.91
Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer (1994) 1.87
Involvement of the CD95 (APO-1/Fas) receptor and ligand system in Helicobacter pylori-induced gastric epithelial apoptosis. J Clin Invest (1998) 1.86
Regulation of CD95/Fas signaling at the DISC. Cell Death Differ (2011) 1.86
B cell-stimulatory factor 1 (BSF-1) promotes growth of helper T cell lines. J Exp Med (1986) 1.82
CD95 (APO-1/Fas)-mediated apoptosis in colon epithelial cells: a possible role in ulcerative colitis. Gastroenterology (1997) 1.81
Cell nucleus and DNA fragmentation are not required for apoptosis. J Cell Biol (1994) 1.75
Interferon gamma and lymphotoxin or tumor necrosis factor act synergistically to induce macrophage killing of tumor cells and schistosomula of Schistosoma mansoni. J Exp Med (1987) 1.75
Most influenza A virus-specific memory cytotoxic T lymphocytes react with antigenic epitopes associated with internal virus determinants. J Exp Med (1984) 1.71
Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ (2004) 1.62
Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer. Ann Oncol (1997) 1.61
Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter? Cancer Res (2001) 1.60
The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations. J Clin Invest (1999) 1.58
Clonal analysis of B cells induced to secrete IgG by T cell-derived lymphokine(s). J Exp Med (1984) 1.58
Lymphokine-induced IgM secretion by clones of neoplastic B cells. Nature (1983) 1.56
Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia. Proc Natl Acad Sci U S A (1999) 1.56
T cell-derived B cell growth and differentiation factors. Dichotomy between the responsiveness of B cells from adult and neonatal mice. J Exp Med (1983) 1.54
HIV-1 protease processes procaspase 8 to cause mitochondrial release of cytochrome c, caspase cleavage and nuclear fragmentation. Cell Death Differ (2002) 1.54
Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res (2000) 1.51
Interleukin 4 mediates autocrine growth of helper T cells after antigenic stimulation. Proc Natl Acad Sci U S A (1986) 1.51
T cell receptor idiotypes are controlled by genes in the heavy chain linkage group and the major histocompatibility complex. Nature (1978) 1.51
High expression of APO-1 (CD95) on T lymphocytes from human immunodeficiency virus-1-infected children. Blood (1994) 1.50
What is the function of IGF-II in postnatal life? Answers from transgenic mouse models. Growth Horm IGF Res (1998) 1.49
Activation of the CD95 (APO-1/Fas) system in T cells from human immunodeficiency virus type-1-infected children. Blood (1996) 1.46
IGF-binding protein-5: flexible player in the IGF system and effector on its own. J Endocrinol (2002) 1.45
Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. Cancer Lett (2000) 1.45
Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J Clin Invest (1994) 1.45
Phosphorylation of FADD/ MORT1 at serine 194 and association with a 70-kDa cell cycle-regulated protein kinase. J Immunol (2000) 1.43
CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway. J Exp Med (1995) 1.43
Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis. Nat Med (1998) 1.42
Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J Biol Chem (1998) 1.41
Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells. Eur J Immunol (1998) 1.40
Vacuolating cytotoxin of Helicobacter pylori induces apoptosis in the human gastric epithelial cell line AGS. Infect Immun (2001) 1.40
Identification of the cytolinker plectin as a major early in vivo substrate for caspase 8 during CD95- and tumor necrosis factor receptor-mediated apoptosis. Mol Cell Biol (2000) 1.40
APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: correlation with bcl-2 oncogene expression. Eur J Immunol (1993) 1.39
The apoptosis-1/Fas protein in human systemic lupus erythematosus. J Clin Invest (1994) 1.37
CXCR4 and CD4 mediate a rapid CD95-independent cell death in CD4(+) T cells. Proc Natl Acad Sci U S A (1998) 1.35
CD95 (APO-1/Fas) induces activation of SAP kinases downstream of ICE-like proteases. Oncogene (1996) 1.33
Resistance of cultured peripheral T cells towards activation-induced cell death involves a lack of recruitment of FLICE (MACH/caspase 8) to the CD95 death-inducing signaling complex. Eur J Immunol (1997) 1.33
Structure of the human APO-1 gene. Eur J Immunol (1994) 1.33
Bcl-xL acts downstream of caspase-8 activation by the CD95 death-inducing signaling complex. J Biol Chem (1998) 1.32
Fc-receptors, Ia-antigens, and immunoglobulin on normal and activated mouse T lymphocytes. J Exp Med (1975) 1.32
Cell surface sialylation plays a role in modulating sensitivity towards APO-1-mediated apoptotic cell death. Cell Death Differ (1995) 1.32
Monoclonal-antibody-mediated apoptosis in adult T-cell leukaemia. Lancet (1990) 1.31
Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur J Immunol (1995) 1.30
Regulation of death receptor-mediated apoptosis pathways. Int J Biochem Cell Biol (2001) 1.30
Human immunodeficiency virus type 1 Tat upregulates interleukin-2 secretion in activated T cells. J Virol (1994) 1.29
Cleavage of FLICE (caspase-8) by granzyme B during cytotoxic T lymphocyte-induced apoptosis. Eur J Immunol (1997) 1.29
Identification of herpes simplex virus type 1 (HSV-1) glycoprotein gC as the immunodominant antigen for HSV-1-specific memory cytotoxic T lymphocytes. J Immunol (1985) 1.28
Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. J Immunol (1994) 1.28
MAPK/ERK signaling in activated T cells inhibits CD95/Fas-mediated apoptosis downstream of DISC assembly. EMBO J (2000) 1.28
Overexpression of insulin-like growth factor-binding protein-2 in transgenic mice reduces postnatal body weight gain. Endocrinology (1999) 1.27
Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol (1995) 1.26
Cytocidal effects of Escherichia coli hemolysin on human T lymphocytes. Infect Immun (1993) 1.25
Expression of c-FLIP(L) and resistance to CD95-mediated apoptosis of monocyte-derived dendritic cells: inhibition by bisindolylmaleimide. Blood (2000) 1.25
Herpes simplex virus type 1 infection of activated cytotoxic T cells: Induction of fratricide as a mechanism of viral immune evasion. J Exp Med (1999) 1.24